159 related articles for article (PubMed ID: 34118892)
1. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?
Yen FS; Lai JN; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
BMC Gastroenterol; 2021 Jun; 21(1):263. PubMed ID: 34118892
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
3. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
Yen FS; Lai JN; Wei JC; Chiu LT; Hwu CM; Hou MC; Hsu CC
PLoS One; 2020; 15(12):e0243783. PubMed ID: 33315940
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
[TBL] [Abstract][Full Text] [Related]
6. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
[TBL] [Abstract][Full Text] [Related]
7. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.
Yen FS; Hou MC; Wei JC; Shih YH; Hwu CM; Hsu CC
BMC Med; 2024 Jan; 22(1):8. PubMed ID: 38172833
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2023 Jun; ():. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.
Yen FS; Wang HC; Pan CW; Wei JC; Hsu CC; Hwu CM
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31544207
[TBL] [Abstract][Full Text] [Related]
10. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
11. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis.
Yen FS; Hou MC; Wei JC; Shih YH; Hsu CY; Hsu CC; Hwu CM
Front Pharmacol; 2022; 13():1049094. PubMed ID: 36618937
[No Abstract] [Full Text] [Related]
12. Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes.
Yen FS; Hou MC; Liu JS; Hsu CC; Hwu CM
Front Med (Lausanne); 2022; 9():962337. PubMed ID: 36687427
[TBL] [Abstract][Full Text] [Related]
13. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes.
Yen FS; Wei JC; Shih YH; Hsu CC; Hwu CM
Sci Rep; 2022 Feb; 12(1):3270. PubMed ID: 35228620
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
15. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
16. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
[TBL] [Abstract][Full Text] [Related]
17. Metformin and the Development of Asthma in Patients with Type 2 Diabetes.
Yen FS; Hsu CC; Shih YH; Pan WL; Wei JC; Hwu CM
Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805869
[TBL] [Abstract][Full Text] [Related]
18. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
Kuo S; Yang CT; Wu JS; Ou HT
Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
[TBL] [Abstract][Full Text] [Related]
19. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
[TBL] [Abstract][Full Text] [Related]
20. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis.
Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS
Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]